Emactuzumab Dosing Regimen for Durable TGCT Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tenosynovial giant cell tumour (TGCT) are limited and often associated with severe side effects, such as liver injury, and there is a need for a safe and effective treatment that can reduce disability and improve joint function in patients with TGCT.
Innovation Solution
A short-term treatment regimen involving up to five cycles of administering an antibody or antigen-binding fragment that specifically binds to colony stimulating factor-1 receptor (CSF-1R), with each cycle consisting of a dose ranging from 200 mg to 1,500 mg followed by a rest period of 6 to 20 days, to manage TGCT.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pexidartinib is administered to treat TGCT, then tumor response is achieved, but serious and potentially fatal liver injury occurs
Solution Approach 1:
The patent extracts the harmful liver toxicity effect from the treatment outcome by selecting an alternative therapeutic agent (emactuzumab) that achieves the desired anti-tumor effect through a different mechanism of action, thereby eliminating the harmful side effect while preserving the beneficial tumor response
Solution Approach 2:
The patent changes the therapeutic parameter from pexidartinib to emactuzumab, which has a different safety profile. This parameter change maintains the efficacy of treating TGCT while altering the side effect profile to avoid serious liver injury
2Reliability
If surgical resection is performed to treat TGCT, then tumor removal is achieved, but significant postsurgical morbidity occurs including removal of major tendons, neurovascular structures, or limbs
Solution Approach 1:
The patent replaces the mechanical surgical intervention with a pharmacological treatment approach using emactuzumab. This substitution eliminates the need for invasive surgical procedures that cause morbidity while achieving tumor response through targeted therapy against CSF-1R
3Duration of action of stationary object
If long-term treatment is administered to maintain durable response, then treatment efficacy is improved, but cumulative toxicity increases
Solution Approach 1:
The patent implements periodic administration of emactuzumab with scheduled dosing intervals. This periodic action maintains therapeutic drug levels for durable tumor response while allowing accumulation of the drug to plateau, thereby preventing continuous increase in cumulative toxicity that would occur with uninterrupted dosing
Data Source
AI summary
The present invention relates to a treatment regime, including an antibody or antigen-binding fragment which is capable of binding specifically to colony stimulating factor-1 receptor (CSF-1R) for use in the treatment of tenosynovial giant cell tumour (TGCT) in a subject, as well as associated uses and methods.